Agenus doses first covid-19 patient with inkt cell therapy

Lexington, mass., nov. 02, 2020 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced the dosing of the first covid-19 patient with agent-797, an allogeneic cell therapy, through its subsidiary, agentus therapeutics. the trial is being led by dr. koen van besien at weill cornell medical college/new york presbyterian hospital. separately, the fda has also cleared agent-797 to treat patients with cancer. cancer trials are expected to commence shortly.
AGEN Ratings Summary
AGEN Quant Ranking